Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


TiO2 photoreaction application in bladder cancer cells

Funder: São Paulo Research Foundation

Funding period
Funding amount
The clinical treatment for bladder cancer is still based on the immunological stimulation of the BCG. However, in some cases this treatment is not successful enough, or in some cases, can cause some collateral effects. Then, the arising of the nanoparticles functionality and nanotechnology, opens a world of possibilities for the development of new antitumoral therapies. The TiO2 is in the list of promising nanomaterials related to biological test. Thought the production of reactive oxygen species (ROS) the TiO2 is capable of activating apoptotic mechanisms in neoplastic cells in reaction to the oxidative stress. Futhermore, it was demonstrated already that the production of ROS, depending of its concentration, acts selectively on the neoplastic cells, in a way that the normal tissues present mechanisms against the accumulated oxidative stress. Because of the superior band gap of 3,0 eV, the NP acts like a semiconductor and can generated ROS when exposed to UV, but it cannot interact with the visible radiation. This limitation can be controlled adding chromophores to the surface of the NPs. Recently, Our group was able to cover the surface with peroxide groups making the Ti(OH)4. The presence of this peroxides in a covalent bound with the NP surface moves the band gap to 2,3 eV. This characteristic gives the Ti(OH)4 NP the capacity of visible light absorption and then the ability to generate superior quantities of ROS when compare with the TiO2. This could have a positive impact in different oncology treatments of cancer cells originated from epithelial tissues with external access, as it is for bladder cancer. In front of this considerations, we propose to evaluate the antitumoral properties of the Ti(OH)4 NP in some cell lineages of bladder cancer and control cells, modifying the time of exposition, concentration and dose/reinforcement. In order to analyze the factors related to the cytotoxically effects and the therapeutic safety.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
A new bladder cancer model based on tissue reprogramming and gene targeting

National Cancer Institute to FLAMINIA TALOS, DAIFENG WANG

USD 203,843
2020 - 2021
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC


  • RCDC

    Urologic Diseases



  • Health Research Areas